To deliver its gene therapy to the inner ear, Decibel Therapeutics adapted the existing, well-understood surgical procedure for cochlear implants. This strategy de-risked the novel therapeutic by leveraging a proven delivery technique and existing surgical expertise, avoiding the need to invent an entirely new procedure.

Eupraxia's strategy for its Eosinophilic Esophagitis (EOE) drug piggybacks on existing procedures. Since EOE patients already undergo endoscopies, the local injection is administered during the same visit. This minimizes the procedural burden on patients and doctors, streamlining adoption and making the hyper-local delivery model feasible and efficient.

The company's AI doesn't try to precisely decode the brain's original signals for specific finger movements. Instead, it's trained to correlate broader brain activity patterns with the user's general intent to grip, making the system more robust and adaptable.

The core innovation is a foundational technology that allows the company to rapidly create new products. By changing the drug, release profile (days, weeks, or months), and physical format (implant, injectable), they can address numerous surgical needs, de-risking the business and creating a scalable pipeline.

The ATX-101 implant was designed with surgeons to be simple and fast to use, fitting into natural pockets in the knee without special training. By saving 5-10 minutes per procedure compared to alternatives, it addresses a critical workflow pain point for physicians and hospitals, enhancing its commercial appeal.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

The next wave of MedTech innovation won't just come from engineers. It will come from creating tools that allow surgeons and clinicians—those who see problems firsthand—to easily prototype and de-risk new device concepts, vastly expanding the market for innovation itself.

The path to printing whole organs is being de-risked through intermediate, commercially viable applications. Companies are already generating value by printing brain tissues for R&D (e.g., for Neuralink) and simpler structures like blood vessels for surgery, proving the technology incrementally.

The core technology of detecting "intent" is viewed as a platform. Once the implant is in place for stroke recovery, it can be trained to detect cognitive lapses and provide real-time prompts, creating a system to assist with conditions like dementia or MCI.